Publications by authors named "Chiara Chiriatti"
Article Synopsis
- Disopyramide has been commonly used to treat left ventricular outflow obstruction (LVOTO) in patients with obstructive hypertrophic cardiomyopathy (oHCM), but its real-world efficacy and the patient characteristics that predict a positive response are still not well understood.
- A study involving 1,527 HCM patients found that about 23% had LVOTO, and among those, 32% responded positively to disopyramide therapy, with most responders being in a less severe NYHA functional class (I/II).
- The treatment showed a generally safe profile, with no major life-threatening arrhythmias reported, but side effects were experienced by 26% of patients, mainly related to anticholinergic
Background: PRKAG2 gene variants cause a syndrome characterized by cardiomyopathy, conduction disease, and ventricular pre-excitation. Only a small number of cases have been reported to date, and the natural history of the disease is poorly understood.
Objectives: The aim of this study was to describe phenotype and natural history of PRKAG2 variants in a large multicenter European cohort.
Purpose Of Review: The management of hypertrophic cardiomyopathy (HCM) has changed considerably over the years, although molecular therapies targeting core mechanisms of the disease are still lacking. This review provides an overview of the contemporary medical approach to patients with HCM, and of promising novel developments hopefully soon to enter the clinical arena.
Recent Findings: Our perception of therapeutic targets for medical therapy in HCM is rapidly evolving.
Background: The clinical course of patients with hypertrophic cardiomyopathy and advanced heart failure (HF) subtended by progressive left ventricular dysfunction has received limited attention. Our aim was to assess the outcome of HF and impact of treatment options including the implantable cardioverter-defibrillator and heart transplantation (HT) in patients with hypertrophic cardiomyopathy evaluated at 2 Italian referral centers >3 decades.
Methods And Results: All-cause mortality and a combined end point including death, HT, or appropriate implantable cardioverter-defibrillator shock were assessed in 71 consecutive patients with HF not related to outflow obstruction (7% of the entire hypertrophic cardiomyopathy cohort) followed up for 6.